MarketInOut Stock Screener Log In | Sign Up
 

Revolution Medicines Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 06/26/2026 16:00
Revolution Medicines Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization36,037 mln
Float194 mln
Earnings Date08/12/2026

Piotroski F-Score

1 / 9
Very weak

1-Year Forecast

187
Fairly priced

Relative Strength

96 / 100
Top performer

Debt / Equity

0.10
Very low leverage

ROE

-79.09
Deeply negative

Dividend Yield

0.00%
No dividend

Business Description

Revolution Medicines is a clinical-stage biotech company focused on developing targeted treatments for cancers driven by RAS gene mutations, a notoriously difficult area of cancer biology. The company has built a pipeline of drug candidates designed to directly block harmful RAS variants, either on their own or alongside other agents that cut off the supporting pathways these cancers rely on. Several of its lead drugs, including daraxonrasib, elironrasib, and zoldonrasib, are currently being tested in clinical trials, with one late-stage study evaluating a combination approach in patients with pancreatic cancer. Founded in 2014 and based in Redwood City, California, the company continues to expand its research into additional RAS mutation types.

Key Fundamentals

EPS-7.27
ROE-79.09
ROIC-442
ROA-58.85
EBITDA, mln-1,336
EV / EBITDA-23.13
EV / EBIT-22.83

Financial Strength

Piotroski F-Score 1 / 9
1-Year Target Price187
Short Ratio4.52
Short % of Float5.76

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 11.71% 94 / 100   
1 Month 19.01% 93 / 100   
2 Months 83.38% 96 / 100   
6 Months 127% 97 / 100   
1 Year 374% 98 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us